0001214659-18-000708.txt : 20180129
0001214659-18-000708.hdr.sgml : 20180129
20180129180017
ACCESSION NUMBER: 0001214659-18-000708
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180126
FILED AS OF DATE: 20180129
DATE AS OF CHANGE: 20180129
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Christensen Jamie
CENTRAL INDEX KEY: 0001599324
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35921
FILM NUMBER: 18556998
MAIL ADDRESS:
STREET 1: C/O MIRATI THERAPEUTICS, INC.
STREET 2: 9393 TOWNE CENTRE DRIVE, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Mirati Therapeutics, Inc.
CENTRAL INDEX KEY: 0001576263
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 462693615
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9393 TOWNE CENTRE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-332-3410
MAIL ADDRESS:
STREET 1: 9393 TOWNE CENTRE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
marketforms-40853.xml
PRIMARY DOCUMENT
X0306
4
2018-01-26
0001576263
Mirati Therapeutics, Inc.
MRTX
0001599324
Christensen Jamie
C/O MIRATI THERAPEUTICS, INC.
9393 TOWNE CENTRE DRIVE, STE 200
SAN DIEGO
CA
92121
false
true
false
false
SVP, Chief Scientific Officer
Common Stock
2018-01-26
4
M
false
12500
5.40
A
15377
D
Common Stock
2018-01-26
4
S
false
12500
26.1138
D
2877
D
Employee Stock Option (Right to Buy)
5.4
2018-01-26
4
M
false
12500
0
D
2027-01-25
Common Stock
12500
37500
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2017.
1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.
This transaction was executed in multiple trades at prices ranging from $25.85 to $26.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
/s/ Vickie Reed, Attorney-in-Fact
2018-01-29